The Emerging Role of Real-world Data in Advanced Breast Cancer Therapy: Recommendations for Collaborative Decision-making

Overview

Journal Breast

Publisher Elsevier

Specialties Endocrinology
Oncology

Date 2021 Dec 27

PMID 34959093

Citations 8

Authors

Paul Cottu

Scott David Ramsey

Oriol Sola-Morales

Patricia A Spears

Lockwood Taylor

Affiliations

Soon will be listed here.

Abstract

Among stakeholders and decision-makers in advanced breast cancer, the demand for insights from real-world data (RWD) is increasing. Although RWD can be used to support decisions throughout different stages of a breast cancer drug's life cycle, barriers exist to its use and acceptance. We propose a collaborative approach to generating and using RWD that is meaningful to multiple stakeholders, and encourage frameworks toward international guidelines to help standardize RWD methodologies to achieve more efficient use of RWD insights.

Citing Articles

Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting.

Rugo H, Layman R, Lynce F, Liu X, Li B, McRoy L ESMO Open. 2025; 10(1):104103.

PMID: 39754979 PMC: 11758200. DOI: 10.1016/j.esmoop.2024.104103.

Palbociclib plus aromatase inhibitors in patients with metastatic breast cancer and cardiovascular diseases: real-world effectiveness.

Brufsky A, Liu X, Li B, McRoy L, Chen C, Makari D Oncologist. 2024; 29(12):1032-1043.

PMID: 39418346 PMC: 11630750. DOI: 10.1093/oncolo/oyae273.

Patterns and outcomes in HR+/HER2- advanced/metastatic breast cancer patients in Brazil receiving palbociclib.

Simon P, Jain A, Guarin A, Piton L, Carvalho C, Lima J Future Oncol. 2024; 20(34):2647-2659.

PMID: 39235063 PMC: 11534102. DOI: 10.1080/14796694.2024.2388022.

Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2- and HER2+ metastatic breast cancer.

Brufsky A, Kwan M, Sandin R, Stergiopoulos S, Karanth S, Cha-Silva A Breast Cancer Res Treat. 2024; 208(2):223-235.

PMID: 39177933 PMC: 11455714. DOI: 10.1007/s10549-024-07469-6.

Towards Agility in Breast Cancer Treatment Principles as Adopted from Agile Software Engineering.

Odeh Y, Al-Balas M J Multidiscip Healthc. 2024; 17:1315-1341.

PMID: 38545433 PMC: 10968939. DOI: 10.2147/JMDH.S449465.

References

De Placido S, Giuliano M, Schettini F, von Arx C, Buono G, Riccardi F . Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results. Breast. 2017; 38:86-91. DOI: 10.1016/j.breast.2017.12.012. View

Arpino G, Michelotti A, Truini M, Montemurro F, Russo S, Palumbo R . Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study. J Cancer Res Clin Oncol. 2015; 142(3):669-78. DOI: 10.1007/s00432-015-2033-z. View

Schettini F, Conte B, Buono G, De Placido P, Parola S, Griguolo G . T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study. ESMO Open. 2021; 6(2):100099. PMC: 8047485. DOI: 10.1016/j.esmoop.2021.100099. View

Perol D, Robain M, Arveux P, Mathoulin-Pelissier S, Chamorey E, Asselain B . The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME). BMJ Open. 2019; 9(2):e023568. PMC: 6398702. DOI: 10.1136/bmjopen-2018-023568. View

Warner J, Jain S, Levy M . Integrating cancer genomic data into electronic health records. Genome Med. 2016; 8(1):113. PMC: 5081968. DOI: 10.1186/s13073-016-0371-3. View

Kim J, Tosteson A, Zauber A, Sprague B, Stout N, Alagoz O . Cancer Models and Real-world Data: Better Together. J Natl Cancer Inst. 2015; 108(2). PMC: 4907359. DOI: 10.1093/jnci/djv316. View

Cocoros N, Arlett P, Dreyer N, Ishiguro C, Iyasu S, Sturkenboom M . The Certainty Framework for Assessing Real-World Data in Studies of Medical Product Safety and Effectiveness. Clin Pharmacol Ther. 2020; 109(5):1189-1196. DOI: 10.1002/cpt.2045. View

Khozin S, Blumenthal G, Pazdur R . Real-world Data for Clinical Evidence Generation in Oncology. J Natl Cancer Inst. 2017; 109(11). DOI: 10.1093/jnci/djx187. View

McDonald L, Malcolm B, Ramagopalan S, Syrad H . Real-world data and the patient perspective: the PROmise of social media?. BMC Med. 2019; 17(1):11. PMC: 6334434. DOI: 10.1186/s12916-018-1247-8. View

10.

DuBenske L, Schrager S, Hitchcock M, Kane A, Little T, McDowell H . Key Elements of Mammography Shared Decision-Making: a Scoping Review of the Literature. J Gen Intern Med. 2018; 33(10):1805-1814. PMC: 6153221. DOI: 10.1007/s11606-018-4576-6. View

11.

Cline M, Liao R, Parsons M, Paten B, Alquaddoomi F, Antoniou A . BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. PLoS Genet. 2018; 14(12):e1007752. PMC: 6324924. DOI: 10.1371/journal.pgen.1007752. View

12.

Beachler D, de Luise C, Yin R, Gangemi K, Cochetti P, Lanes S . Predictive model algorithms identifying early and advanced stage ER+/HER2- breast cancer in claims data. Pharmacoepidemiol Drug Saf. 2018; 28(2):171-178. DOI: 10.1002/pds.4681. View

13.

Le Saux O, Lardy-Cleaud A, Frank S, Debled M, Cottu P, Pistilli B . Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national study. Eur J Cancer. 2019; 118:131-141. DOI: 10.1016/j.ejca.2019.06.014. View

14.

Bolislis W, Fay M, Kuhler T . Use of Real-world Data for New Drug Applications and Line Extensions. Clin Ther. 2020; 42(5):926-938. DOI: 10.1016/j.clinthera.2020.03.006. View

15.

Zou K, Li J, Imperato J, Potkar C, Sethi N, Edwards J . Harnessing Real-World Data for Regulatory Use and Applying Innovative Applications. J Multidiscip Healthc. 2020; 13:671-679. PMC: 7383026. DOI: 10.2147/JMDH.S262776. View

16.

von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008; 61(4):344-9. DOI: 10.1016/j.jclinepi.2007.11.008. View

17.

Wedam S, Fashoyin-Aje L, Bloomquist E, Tang S, Sridhara R, Goldberg K . FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer. Clin Cancer Res. 2019; 26(6):1208-1212. DOI: 10.1158/1078-0432.CCR-19-2580. View

18.

Cottu P, Coudert B, Perol D, Doly A, Manson J, Aujoulat O . Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2-targeted treatments: Results from the french personalized reimbursement model database.... Eur J Cancer. 2020; 141:209-217. DOI: 10.1016/j.ejca.2020.10.012. View

19.

Sacristan J, Lizan L, Comellas M, Garrido P, Avendano C, Cruz-Hernandez J . Perceptions of Oncologists, Healthcare Policy Makers, Patients and the General Population on the Value of Pharmaceutical Treatments in Oncology. Adv Ther. 2016; 33(11):2059-2068. PMC: 5083772. DOI: 10.1007/s12325-016-0415-5. View

20.

Valenti V, Ramos J, Perez C, Capdevila L, Ruiz I, Tikhomirova L . Increased survival time or better quality of life? Trade-off between benefits and adverse events in the systemic treatment of cancer. Clin Transl Oncol. 2019; 22(6):935-942. DOI: 10.1007/s12094-019-02216-6. View